Charles River Laboratories CRL Add - Incremental shares under stock-based compensation plans (in shares)

Add - Incremental shares under stock-based compensation plans (in shares) at other companies

Bio-Rad LaboratoriesBIO

——

Thermo Fisher ScientificTMO

——

West Pharmaceutical ServicesWST

——

PlexusPLXS

——

Other financials

Income statement

See full

Revenue$995.8M+1.2%

Gross profit$349.0M-3.5%

Operating income$119.9M+60.6%

Net income-$14.8M-158%

EPS (diluted)-$0.30-160%

Balance sheet

See full

Cash & equivalents$198.2M-14.5%

Total debt$3.1B+1.9%

Total equity$2.9B-7.9%

Total assets$7.7B+2.0%

Cash flow

See full

Operating cash flow$41.1M-76.1%

CapEx$55.9M-5.8%

Free cash flow-$14.8M-113%

Valuation

See full

Market cap$8.91B+10.3%

Enterprise value$11.79B+8.5%

P/S2.2×+0.2×

Profitability

See full

Gross margin84.7%—

Operating margin13%-2.4pp

Net margin-4.6%—

FCF margin9.7%-4.3pp

Returns & leverage

See full

Return on equity-6%—

Debt / equity1×+0.1×

Current ratio1.4×-0.1×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements.

The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's add - incremental shares under stock-based compensation plans (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Charles River Laboratories's add - incremental shares under stock-based compensation plans (in shares)?: Charles River Laboratories (CRL) reported add - incremental shares under stock-based compensation plans (in shares) of $0 in Q1 2026.
How has Charles River Laboratories's add - incremental shares under stock-based compensation plans (in shares) changed year-over-year?: Charles River Laboratories's add - incremental shares under stock-based compensation plans (in shares) decreased by 100.0% year-over-year, from $176K to $0.